(Health-NewsWire.Net, January 18, 2016 ) The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population. Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously. Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the global human insulin market. Growing demand of biosimilar drugs, due to its cost effectiveness, pose an opportunity for the growth of the human insulin market. In addition, increasing usage of insulin pens for the administration of insulin helps to inject the accurate dose of insulin at a time. However, high insulin analog cost and strict regulatory requirements for approval of human insulin are inhibiting the growth of the global human insulin market.
On the basis of type of human insulin, the modern human insulin commands the larger share in the global market. The modern human insulin is also expected to grow at a CAGR (of 13%) than traditional human insulin during 2015 to 2020. The modern human insulin can be further categorized as long acting human insulin, rapid acting human insulin and premixed human insulin; wherein, the long acting human insulin commands the largest share in modern human insulin market but the premixed human insulin exhibited the highest growth rate.
Request for Report Sample of Global Human Insulin Market Research: https://www.psmarketresearch.com/enquiry-form.php?enqid=176&title=Report%20sample
Also, in Asia-Pacific, several government initiatives are implemented to create awareness about prevention and treatment of diabetes. The government is also taking initiatives to improve healthcare infrastructure and provide treatment in rural areas. In Asia-Pacific, the human insulin market is expected to witness CAGR of 13.9% during the period 2015 to 2020, to achieve $12,074.3 million value by 2020.
Browse more reports on healthcare: https://www.psmarketresearch.com/industry-report/healthcare
The global human insulin market has a fragmented structure with large number of companies operating in the market. The key players in the human insulin market include Sanofi, Novo Nordisk A/S, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co., and Julphar.
Human Insulin Market Segmentation
Human Insulin Market by type
• Traditional human insulin
• Modern human insulin
Traditional Human Insulin Market by type
• Short acting human insulin
• Intermediate acting human insulin
• Premixed human insulin
Modern Human Insulin Market by type
• Long acting human insulin
• Rapid acting human insulin
• Premixed human insulin
Human Insulin Market by Brand
Human Insulin Market by Region
• North America
o The U.S.
o The U.K.
• Rest of the World (ROW)
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY -10016
Toll-free: +1-888-778-7886 (USA/Canada)
P&S Market Research